dalantercept

Acceleron Pharma Announced That The Gog Has Sponsored Its Phase 2 Study of Dalantercept
Feb 18, 2013
Acceleron Pharma has announced that the Gynecologic Oncology Group (GOG) has sponsored its phase 2 study of dalantercept. Patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer are taking part in the ...

Tags: clinical trial, dalantercept, Acceleron Pharma